About Indigo Biosciences
Founded in 2005, INDIGO Biosciences specialises in cell-based reporter assays and in vitro screening technologies that support drug discovery, safety assessment and environmental toxicology research. The company develops proprietary mammalian cell-based assay systems designed to measure functional activity against a broad range of biological targets, enabling researchers to evaluate agonist, antagonist and pathway-specific responses with sensitive and reproducible methods. Its expertise spans nuclear receptors, G protein-coupled receptors (GPCRs), cytokine receptors, growth factor receptors and transcription factors, supporting applications in lead discovery, mechanism-of-action studies, ADME and safety pharmacology, and environmental monitoring.
INDIGO Biosciences' development of their proprietary process CryoMite™, provided the ability to cryo-preserve cells used in screening services for shipping and long-term storage, enabling sceintists to use their robust cell-based reporter assays within their own labs. Their portfolio includes all-inclusive luciferase reporter assay kits supplied with engineered reporter cells, optimised media, reference compounds and detection reagents for streamlined functional screening workflows. The company offers assay platforms targeting receptors and signalling pathways relevant to metabolic disease, inflammation, oncology, neuroscience and toxicology, alongside custom assay development and contract screening services. Additional capabilities support environmental toxicology and water reuse testing, allowing researchers to assess biological activity in complex samples using human-relevant cellular models. These tools are widely used for target validation, compound profiling, functional characterisation and toxicity assessment across academic, government and biopharmaceutical laboratories.
Europa Biosite subsidiaries distribute Absea products in Austria, Belgium, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxemburg, Netherlands, Norway, Sweden, Switzerland and the United Kingdom.